Biora Therapeutics, Inc.
BIORQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$365
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $365.00 |
|---|---|
| Enterprise Value | $35.40 Million |
| Earnings per Share | $-78.7 |
| Beta | 5.31 |
| Outstanding Shares | 3,652,862 |
Return
| Return on Equity | 29.58% |
|---|---|
| Return on Assets | -217.44% |
| Return on Invested Capital | 57.47% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 20.07 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.09 |
| Debt to Equity | -0.36 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-202.78
Consensus analyst estimateRevenue Estimate
$25.41 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-202.78
Consensus analyst estimateRevenue Estimate
$25.41 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Progenity Inc
58 employees
CEO: Harry Stylli
Biora Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing innovative oral biotherapeutics. The company's core efforts include: 1. Targeted Therapeutics Program: This initiative employs an advanced, ing...